EGFR and non-small cell lung carcinoma: The presented data show that functional EGFR genetic variants, such as rs712829, rs712830, and rs2227983, may significantly modify the clinical outcomes in patients with inoperable NSCLC receiving DNA damage-inducing anticancer therapy, such as RT and platinum-based CHTRT.